Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
540
|
Wed, 8/1/2018,
11:35 AM -
12:20 PM
|
CC-West Hall B
|
|
SPEED: Clinical Trial Design, Longitudinal Analysis, and Other Topics in Biopharmaceutical Statistics — Contributed Poster Presentations
|
|
Biopharmaceutical Section
|
|
Chair(s): Paul McNicholas, McMaster University
|
|
Oral Presentations
for this session.
|
|
21:
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
|
|
22:
|
A Novel Blind Start Study Design to Investigate Vestronidase Alfa for Mucopolysaccharidosis VII, an Ultra-Rare Genetic Disease
Wenjie Song, Ultragenyx Pharmaceutical Inc; Chao-Yin Chen, Ultragenyx Pharmaceutical Inc; Christine Haller, Ultragenyx Pharmaceutical Inc; Emil Kakkis, Ultragenyx Pharmaceutical Inc
|
|
23:
|
Statistical Models for Longitudinal Analysis of Preclinical Efficacy Screens
William Forrest, Genentech, Inc; Bruno Alicke, Genentech; Oleg Mayba, Genentech; Alice Starr, Genentech
|
|
24:
|
Treatment Effect Estimation in Subgroups: a Comparative Study
Weihua Cao, Novartis Pharmaceutical Corp; Bjoern Holzhauer, Novartis Pharma AG; Steffen Ballerstedt, Novartis Pharma AG; Dong Xi, Novartis Pharmaceuticals; Ieuan Jones, Novartis Pharma AG
|
|
25:
|
Sample Size Formulae and Application for the Two-Stage Continual Reassessment Method (CRM)
Cody Chiuzan, Columbia University; Ying Kuen Ken Cheung, Columbia University; Zilan Chai, Columbia University
|
|
26:
|
Single Item Analysis of Patient-Reported Outcome Measures in a Phase III Randomized Controlled Trial
Stacie Hudgens, Clinical Outcome Solutions; Lysbeth Floden, Clinical Outcome Solutions
|
|
28:
|
Incorporating Intermediate Binary Responses into Interim Analysis of a Long-Term Binary Endpoint
Jingjing Chen, Takeda Pharmaceuticals; Tina Liu, Takeda Pharmaceuticals; Andrejus Parfionovas, Takeda Pharmaceuticals; Cong Han, Takeda Pharmaceuticals; Xiaopan Yao, Takeda Pharmaceuticals
|
|
29:
|
MMRM Estimates Consideration for Longitudinal Data in Clinical Trials
Zheng (Jason) Yuan, Vertex Pharmaceuticals; Yaohua Zhang, Vertex Pharmaceuticals; Chenkun Wang, Vertex Pharmaceuticals; Bingming Yi, Vertex Pharmaceuticals
|
|
30:
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
|
|
31:
|
Sample Size Estimation for Stratified Cluster Randomized Trials with Binary Outcomes
Lee Kennedy-Shaffer, Harvard University; Michael David Hughes, Harvard University
|
|
32:
|
Estimation of Peak Expiratory Flow Under Stochastic Differential Equations
Shan Yang, Merck & Co Inc
|
|
33:
|
A Novel Confidence Interval for a Single Proportion in the Presence of Clustered Binary Outcome Data
Meghan Short, Boston University School of Public Health; Joseph M. Massaro, Boston University
|
|
34:
|
Analysis of Multiple Thresholds in a Responder Analysis of Patient-Reported Outcome Measures
Lysbeth Floden, Clinical Outcome Solutions; Melanie L Bell, University of Arizona; Stacie Hudgens, Clinical Outcome Solutions
|
|
35:
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
|
36:
|
Assessing MCP-Mod Relative to Pairwise Comparisons and Trend Tests in Dose-Ranging Design and Analysis
Anran Wang, Merck & Co Inc; Fang Liu, Merck & Co., Inc; Sammy Yuan, Merck; Man (Mandy) Jin, Merck & Co., Inc.; Meihua Wang, Merck & Co.; Akshita Chawla, Merck & Co Inc; Pranab Kumar Mitra, Merck & Co Inc; Robin Mogg, Merck Research Laboratories
|
|
37:
|
Exposure-Response Analysis with Random Forest
Zifang Guo, Merck; Thomas Jemielita, Merck & Co.; John Kang, Merck
|
|
38:
|
Statistical Considerations of Single Pivotal Vs Two Replicated Confirmatory Studies
Zijiang Yang, Janssen R&D
|
|
39:
|
Reducing the Effects of Misclassification in Sequential Multiple Assignment Randomized Trials (SMART)
Jun He, Virginia Commonwealth University; Donna McClish, Virginia Commonwealth University; Roy T Sabo, Virginia Commonwealth University
|
